Nikhil Prasad Fact checked by:Thailand Medical News Team Jun 16, 2024 4 months, 1 week, 2 days, 19 hours, 20 minutes ago
Medical News: The Link Between Antihistamines and Liver Cancer
Have you ever wondered if the medications you take could have unexpected effects on your health? A recent study by researchers from Weiss Memorial Hospital/University of Illinois-USA, National Cheng Kung University-Taiwan, Chung Shan Medical University Hospital-Taiwan and Perelman School of Medicine, University of Pennsylvania-USA that is covered in this
Medical News report, has revealed a surprising connection between antihistamines, commonly used for allergy relief, and an increased risk of liver cancer in patients with viral hepatitis. This discovery highlights the importance of understanding the broader impacts of our medications.
Antihistamines and Liver Cancer - Unveiling Hidden Risks in Hepatitis Patients
Understanding Hepatitis and Its Risks
Hepatitis is a condition marked by inflammation of the liver, often caused by viral infections. The two most common types are hepatitis B and hepatitis C. Both can lead to severe liver damage over time, potentially resulting in liver cancer. Liver cancer is a serious disease that significantly affects a person's quality of life and is a leading cause of cancer-related deaths worldwide. The prevalence of hepatitis B virus (HBV) was reported to be approximately 3.9% in 2016. As for hepatitis C, the viremic prevalence was reported to be 0.78% in women and 0.13% in children.
The Role of Antihistamines
Antihistamines are drugs used to treat allergic reactions by blocking the effects of histamine, a substance in the body that causes allergy symptoms. They are commonly prescribed for conditions like hay fever, hives, and itching. However, their use in patients with viral hepatitis has raised new concerns.
The Study: What Did Researchers Find?
A multi-center cohort study involving 7,748 patients with hepatitis B or C investigated the relationship between antihistamine use and liver cancer risk. The study spanned over 14 years, from January 2008 to March 2022. Researchers followed patients for up to five years, tracking the incidence of new liver cancer cases.
-Higher Risk in Antihistamine Users: The study found that patients with viral hepatitis who used antihistamines had a significantly higher risk of developing liver cancer. The incidence rate was 12.58 per 1,000 person-years for antihistamine users, compared to 3.88 per 1,000 person-years for non-users.
-Impact on Hepatitis C Patients: The risk was particularly pronounced in patients with hepatitis C. Antihistamine users with hepatitis C had an incidence rate of 15.73 per 1,000 person-years, while non-users had a rate of 4.79 per 1,000 person-years. This translates to a more than threefold increase in liver cancer risk for these patients.
-No Significant Impact in Hepatitis B Alone: For patients with hepatitis B alone, the increased risk of liver cancer was not statistically significant after adjusting for othe
r factors.
The Bigger Picture: Why Does This Happen?
The exact mechanism behind the increased cancer risk is not fully understood. One theory is that chronic inflammation from hepatitis may interact with antihistamines in a way that promotes cancer development. Histamine plays various roles in the body, including regulating immune responses. Inflammatory reactions linked to histamine might inadvertently contribute to cancer progression in the liver.
What Does This Mean for Patients?
For patients with viral hepatitis, especially those with hepatitis C, this study suggests that caution is needed when using antihistamines. Doctors might need to reconsider prescribing these medications to such patients or closely monitor their liver health if antihistamines are necessary.
Moving Forward: Need for Further Research
The findings of this study underscore the need for further research to confirm these results and explore the underlying mechanisms. Long-term studies and randomized controlled trials could provide more definitive answers. Meanwhile, patients should discuss any concerns with their healthcare providers to make informed decisions about their treatment options.
Conclusion: A Call for Awareness
This study highlights an unexpected link between a common medication and a serious health risk. It serves as a reminder of the complex interactions between different aspects of our health and the importance of ongoing research in uncovering these connections. As we learn more, we can better protect our health and make more informed choices about the treatments we use.
The study findings were published in the peer reviewed journal: Viruses.
https://www.mdpi.com/1999-4915/16/6/940
For the latest about antihistamines, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/global-misuse-of-antihistamines-and-dangers-of-long-term-usage
https://www.thailandmedical.news/news/covid-19-treatments-study-shows-using-dual-antihistamines-such-as-cetirizine-and-famotidine-helps-pulmonary-symptoms-in-covid-19-patients
https://www.thailandmedical.news/news/university-of-california-study-shows-that-common-otc-antihistamines-such-as-diphenhydramine-can-help-alleviate-certain-long-covid-symptoms
https://www.thailandmedical.news/news/covid-19-drugs-spanish-researchers-find-that-early-treatment-with-antihistamines-like-cetirizine-can-reduce-risk-of-covid-19-hospitalization
https://www.thailandmedical.news/news/uk-researchers-find-that-t-cell-perturbations-persist-for-several-months-after-mild-covid-19-and-contributes-to-long-covid-antihistamines-help
https://www.thailandmedical.news/news/italian-clinical-study-reveals-promising-breakthrough-in-long-covid-treatment-antihistamines-improve-cardiovascular-symptoms-and-more
Share
Tweet
Share
